Patents by Inventor Glenn Noronha

Glenn Noronha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190269702
    Abstract: The present invention relates to methods, devices, and compositions for treating ocular disorders such as uveitis, macular edema associated with uveitis, and diabetic macular edema. For example, the methods include treatment of subjects having macular edema associated with non-infectious uveitis, or diabetic macular edema, by administering to the subjects a triamcinolone composition via non-surgical administration to the suprachoroidal space (SCS) of the eye.
    Type: Application
    Filed: March 5, 2019
    Publication date: September 5, 2019
    Inventors: Daniel WHITE, Glenn NORONHA, Jennifer KISSNER
  • Publication number: 20190240208
    Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
    Type: Application
    Filed: September 7, 2018
    Publication date: August 8, 2019
    Inventors: Vladimir ZARNITSYN, Samirkumar PATEL, Daniel WHITE, Glenn NORONHA, Brian BURKE
  • Publication number: 20190133933
    Abstract: The current disclosure relates to formulations and methods for reducing intraocular pressure (IOP) in the eye of a subject in need thereof. The disclosure also relates to formulations and methods for reducing intraocular pressure (IOP) related to glaucoma in a subject. The methods provided include non-surgically administering a non-pharmacologically active injectable formulation to the eye of the subject by using an apparatus that is suitable for delivering the formulations. The methods provided also include placing a solid implant into the eye of the subject to create a controlled space in the suprachoroidal space (SCS) or the supraciliary space of the eye of the subject in need thereof. The present disclosure further comprises facilitating and improving the aqueous outflows in the eye through the trabecular meshwork outflow pathway and/or uveoscleral outflow pathway and thereby decreasing the intraocular pressure.
    Type: Application
    Filed: May 1, 2017
    Publication date: May 9, 2019
    Inventors: Richard BECKMAN, Jesse YOO, Rafael Victor ANDINO, Glenn NORONHA, Samirkumar PATEL, Donna TARABORELLI, Vladimir ZARNITSYN
  • Publication number: 20180325884
    Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
    Type: Application
    Filed: July 20, 2018
    Publication date: November 15, 2018
    Inventors: Vladimir ZARNITSYN, Samirkumar PATEL, Daniel WHITE, Glenn NORONHA, Brian BURKE
  • Publication number: 20180092897
    Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
    Type: Application
    Filed: December 4, 2017
    Publication date: April 5, 2018
    Inventors: Vladimir Zarnitsyn, Samirkumar Patel, Daniel White, Glenn Noronha, Brian Burke
  • Patent number: 9931330
    Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: April 3, 2018
    Assignee: CLEARSIDE BIOMEDICAL, INC.
    Inventors: Vladimir Zarnitsyn, Samirkumar Patel, Daniel White, Glenn Noronha, Brian Burke
  • Publication number: 20180042765
    Abstract: The present invention relates to a methods and devices for treating uveitis, macular edema associated with uveitis and macular edema associated with retinal vein occlusion in a human subject in need thereof. In certain aspects, devices provided herein include a medicament container defining a lumen configured to contain a medicament, a distal end portion of the medicament container including a coupling portion configured to be removably coupled to a needle assembly, a proximal end portion of the medicament container including a flange and a longitudinal shoulder; a piston assembly including a distal end portion movably disposed within the lumen of the medicament container; and a handle coupled to a proximal end portion of the piston assembly.
    Type: Application
    Filed: June 17, 2015
    Publication date: February 15, 2018
    Inventors: Glenn NORONHA, Christopher John BROOKS, Rafael Victor ANDINO, Samirkumar PATEL, Daniel WHITE
  • Publication number: 20180028516
    Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
    Type: Application
    Filed: March 9, 2017
    Publication date: February 1, 2018
    Inventors: Vladimir ZARNITSYN, Samirkumar PATEL, Daniel WHITE, Glenn NORONHA, Brian BURKE
  • Publication number: 20170333416
    Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
    Type: Application
    Filed: August 9, 2017
    Publication date: November 23, 2017
    Inventors: Vladimir ZARNITSYN, Samirkumar PATEL, Daniel WHITE, Glenn NORONHA, Brian BURKE
  • Patent number: 9636332
    Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: May 2, 2017
    Assignee: CLEARSIDE BIOMEDICAL, INC.
    Inventors: Vladimir Zarnitsyn, Samirkumar Patel, Daniel White, Glenn Noronha, Brian Burke
  • Patent number: 9572800
    Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: February 21, 2017
    Assignee: CLEARSIDE BIOMEDICAL, INC.
    Inventors: Vladimir Zarnitsyn, Samirkumar Patel, Daniel White, Glenn Noronha, Brian Burke, Jennifer Kissner
  • Publication number: 20160213662
    Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
    Type: Application
    Filed: March 31, 2016
    Publication date: July 28, 2016
    Inventors: Vladimir ZARNITSYN, Samirkumar PATEL, Daniel WHITE, Glenn NORONHA, Brian BURKE
  • Publication number: 20160206628
    Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
    Type: Application
    Filed: January 20, 2016
    Publication date: July 21, 2016
    Applicant: Clearside Biomedical, Inc.
    Inventors: Vladimir ZARNITSYN, Samirkumar PATEL, Daniel WHITE, Glenn NORONHA, Brian BURKE
  • Publication number: 20150258120
    Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
    Type: Application
    Filed: November 8, 2013
    Publication date: September 17, 2015
    Inventors: Vladimir Zarnitsyn, Samirkumar Patel, Daniel White, Glenn Noronha, Brian Burke
  • Patent number: 8604042
    Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: December 10, 2013
    Assignee: TargeGen, Inc.
    Inventors: Glenn Noronha, Chi Ching Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved P. Pathak, Daniel L. Lohse, John D. Hood, Richard M. Soll
  • Patent number: 8481536
    Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: July 9, 2013
    Assignee: TargeGen, Inc.
    Inventors: Xianchang Gong, Kathy Barrett, Jianguo Cao, Colleen Gritzen, Glenn Noronha, John D. Hood, Chi Ching Mak, Andrew McPherson, Ved Prakash Pathak, Joel Renick, Richard M. Soll, Ute Splittgerber, Wolfgang Wrasidlo, Binqi Zeng, Ningning Zhao, Elena Dneprovskaia
  • Patent number: 8138199
    Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: March 20, 2012
    Assignee: TargeGen, Inc.
    Inventors: Glenn Noronha, John D. Hood, Richard M. Soll
  • Patent number: 8133900
    Abstract: The invention provides methods of treating a disease selected from systemic sclerosis, rheumatoid arthritis, mastocytosis, and chronic eosinophilic leukemia comprising administering biaryl meta-pyrimidine compounds having the general structure (A) to a subject in need thereof. The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the JAK kinase family, and various other specific receptor and non-receptor kinases.
    Type: Grant
    Filed: October 14, 2008
    Date of Patent: March 13, 2012
    Assignee: Targegen, Inc.
    Inventors: John D. Hood, Glenn Noronha
  • Publication number: 20110294796
    Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: December 28, 2010
    Publication date: December 1, 2011
    Applicant: TargeGen, Inc.
    Inventors: Xianchang Gong, Kathy Barrett, Jianguo Cao, Colleen Gritzen, John D. Hood, Chi Ching Mak, Andrew McPherson, Ved Prakash Pathak, Joel Renick, Richard M. Soll, Ute Splittgerber, Wolfgang Wrasidlo, Ningning Zhao, Elena Dneprovskaia, Binqi Zeng, Glenn Noronha
  • Patent number: 8030487
    Abstract: Compounds having the general structure (A) are provided. The compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, Vegfr and various other specific receptor and non-receptor kinases.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: October 4, 2011
    Assignee: TargeGen, Inc.
    Inventors: Glenn Noronha, Jianguo Cao, Colleen Gritzen, Chi Ching Mak, Andrew McPherson, Ved P. Pathak, Joel Renick, Richard M. Soll, Binqi Zeng, Elena Dneprovskaia